ZA200600915B - Use of combination of an epidermal growth factor receptor inhibitor and cytotoxic agents for treatment and inhibition of cancer - Google Patents
Use of combination of an epidermal growth factor receptor inhibitor and cytotoxic agents for treatment and inhibition of cancer Download PDFInfo
- Publication number
- ZA200600915B ZA200600915B ZA200600915A ZA200600915A ZA200600915B ZA 200600915 B ZA200600915 B ZA 200600915B ZA 200600915 A ZA200600915 A ZA 200600915A ZA 200600915 A ZA200600915 A ZA 200600915A ZA 200600915 B ZA200600915 B ZA 200600915B
- Authority
- ZA
- South Africa
- Prior art keywords
- carbon atoms
- alkyl
- kinase inhibitor
- egfr kinase
- combination
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 47
- 229940127089 cytotoxic agent Drugs 0.000 title claims description 26
- 239000002254 cytotoxic agent Substances 0.000 title claims description 26
- 231100000599 cytotoxic agent Toxicity 0.000 title claims description 26
- 201000011510 cancer Diseases 0.000 title claims description 25
- 238000011282 treatment Methods 0.000 title claims description 16
- 230000005764 inhibitory process Effects 0.000 title description 13
- 102000001301 EGF receptor Human genes 0.000 title description 11
- 108060006698 EGF receptor Proteins 0.000 title description 11
- 239000003112 inhibitor Substances 0.000 title description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 151
- 125000000217 alkyl group Chemical group 0.000 claims description 37
- -1 FOLFOX4 Chemical compound 0.000 claims description 26
- 229940121647 egfr inhibitor Drugs 0.000 claims description 25
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 22
- 229960002949 fluorouracil Drugs 0.000 claims description 22
- 241000124008 Mammalia Species 0.000 claims description 18
- 229930012538 Paclitaxel Natural products 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 229960001592 paclitaxel Drugs 0.000 claims description 16
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 16
- 238000002648 combination therapy Methods 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 206010009944 Colon cancer Diseases 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 11
- 229960004316 cisplatin Drugs 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 8
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 229960004117 capecitabine Drugs 0.000 claims description 8
- JYEFSHLLTQIXIO-SMNQTINBSA-N folfiri regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 claims description 8
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 125000005042 acyloxymethyl group Chemical group 0.000 claims description 6
- 125000004849 alkoxymethyl group Chemical group 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- ITGIYLMMAABTHC-ONEGZZNKSA-N (e)-4-(dimethylazaniumyl)but-2-enoate Chemical compound CN(C)C\C=C\C(O)=O ITGIYLMMAABTHC-ONEGZZNKSA-N 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000001246 bromo group Chemical group Br* 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000004970 halomethyl group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 3
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 3
- 125000005422 alkyl sulfonamido group Chemical group 0.000 claims description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 3
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 2
- 125000000033 alkoxyamino group Chemical group 0.000 claims description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 2
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 2
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 6
- WVUNYSQLFKLYNI-UHFFFAOYSA-N N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide Chemical compound C=12C=C(NC(=O)C=CCN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-UHFFFAOYSA-N 0.000 claims 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 3
- AIQFOGOHLOICRK-UHFFFAOYSA-N 6-amino-4-(3-chloro-4-fluoroanilino)-7-ethoxyquinoline-3-carbonitrile Chemical compound C=12C=C(N)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 AIQFOGOHLOICRK-UHFFFAOYSA-N 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 57
- 230000004614 tumor growth Effects 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 17
- 229940079593 drug Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 238000000692 Student's t-test Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 108091005682 Receptor kinases Proteins 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000002074 deregulated effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 241000353355 Oreosoma atlanticum Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 239000010520 ghee Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 108700023468 protein-bound SN-C polysaccharide Proteins 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49213203P | 2003-08-01 | 2003-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200600915B true ZA200600915B (en) | 2007-12-27 |
Family
ID=34215843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200600915A ZA200600915B (en) | 2003-08-01 | 2006-01-31 | Use of combination of an epidermal growth factor receptor inhibitor and cytotoxic agents for treatment and inhibition of cancer |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20050026933A1 (fr) |
| EP (1) | EP1648516A2 (fr) |
| JP (1) | JP2007501238A (fr) |
| KR (1) | KR20060054412A (fr) |
| CN (1) | CN1832757A (fr) |
| AR (1) | AR045179A1 (fr) |
| AU (1) | AU2004266572A1 (fr) |
| BR (1) | BRPI0413255A (fr) |
| CA (1) | CA2533126A1 (fr) |
| CO (1) | CO5640151A2 (fr) |
| CR (1) | CR8181A (fr) |
| EC (1) | ECSP066341A (fr) |
| IL (1) | IL173081A0 (fr) |
| MX (1) | MXPA06001110A (fr) |
| NO (1) | NO20060398L (fr) |
| RU (1) | RU2006106267A (fr) |
| TW (1) | TW200515910A (fr) |
| WO (1) | WO2005018677A2 (fr) |
| ZA (1) | ZA200600915B (fr) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100966395B1 (ko) * | 2002-03-29 | 2010-06-28 | 엑손모빌 케미칼 패턴츠 인코포레이티드 | 올레핀의 올리고머화 |
| EP1490314A1 (fr) * | 2002-03-29 | 2004-12-29 | ExxonMobil Chemical Patents, Inc. a Corporation of the State of Delaware | Preparation d'hydrocarbures alkylaromatiques et de sulfonates d'alkylaryle |
| KR101289774B1 (ko) | 2004-03-31 | 2013-08-07 | 다나-파버 캔서 인스티튜트 인크. | 표피성장인자 수용체를 표적으로 하는 치료에 대한 암의반응성을 결정하는 방법 |
| JP2008501654A (ja) * | 2004-06-03 | 2008-01-24 | エフ．ホフマン−ラ ロシュ アーゲー | シスプラチンとｅｇｆｒ阻害剤を用いた治療 |
| BRPI0511780A (pt) * | 2004-06-03 | 2008-01-15 | Hoffmann La Roche | tratamento com oxoliplatina e um inibidor de egrf |
| CN113952459B (zh) | 2005-02-03 | 2025-02-11 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
| EP2594631A1 (fr) | 2005-04-05 | 2013-05-22 | Cellpoint Diagnostics | Dispositifs et procédés détection de cellules tumorales circulantes et d'autres particules |
| JP2008536847A (ja) * | 2005-04-14 | 2008-09-11 | ワイス | ゲフィニチブ耐性患者における上皮増殖因子レセプター（ｅｇｆｒ）キナーゼインヒビターの使用 |
| SG164368A1 (en) * | 2005-07-18 | 2010-09-29 | Bipar Sciences Inc | Treatment of cancer |
| US20080292729A1 (en) * | 2005-07-21 | 2008-11-27 | Nuvo Research Inc. | Stabilized Chlorite Solutions in Combination with Fluoropyrimidines for Cancer Treatment |
| CN103110948A (zh) | 2005-11-04 | 2013-05-22 | 惠氏公司 | mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合 |
| WO2007139930A2 (fr) * | 2006-05-26 | 2007-12-06 | Bayer Healthcare Llc | Associations de médicaments comportant des urées de diaryle substituées pour le traitement du cancer |
| US20070292883A1 (en) * | 2006-06-12 | 2007-12-20 | Ossovskaya Valeria S | Method of treating diseases with PARP inhibitors |
| US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| CA2662337A1 (fr) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition de la synthese d'acides gras au moyen d'inhibiteurs parp et methodes de traitement associees |
| CA2662517A1 (fr) * | 2006-09-05 | 2008-03-13 | Jerome Moore | Traitement du cancer |
| JP2010503696A (ja) * | 2006-09-13 | 2010-02-04 | ヌベロ， インコーポレイテッド | 癌を処置するための方法 |
| DE102007024470A1 (de) | 2007-05-24 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| NZ586123A (en) * | 2007-11-12 | 2012-12-21 | Bipar Sciences Inc | Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors |
| RU2480211C2 (ru) * | 2007-11-12 | 2013-04-27 | Байпар Сайенсиз, Инк. | Лечение рака молочной железы с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами |
| RU2010128107A (ru) * | 2007-12-07 | 2012-01-20 | Байпар Сайенсиз, Инк. (Us) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp |
| EP2072502A1 (fr) | 2007-12-20 | 2009-06-24 | Bayer Schering Pharma Aktiengesellschaft | Dérivés de chinoline substitués par du sulfoximide et dérivés de chinazoline en tant qu'inhibiteurs de kinase |
| CN102641270A (zh) | 2008-06-17 | 2012-08-22 | 惠氏有限责任公司 | 含有hki-272和长春瑞滨的抗肿瘤组合 |
| HUE032958T2 (hu) * | 2008-08-04 | 2017-11-28 | Wyeth Llc | 4-Anilino-3-ciano-kinolinok és capecitabin antineoplasztikus kombinációi |
| MX2011002484A (es) * | 2008-09-05 | 2011-09-26 | Avila Therapeutics Inc | Algoritmo para diseñar inhibidores irreversibles. |
| LT3000467T (lt) | 2009-04-06 | 2023-04-11 | Wyeth Llc | Krūties vėžio gydymo schema naudojant neratinibą |
| NZ620174A (en) | 2009-09-16 | 2016-08-26 | Celgene Avilomics Res Inc | Protein kinase conjugates and inhibitors |
| EP2498751B1 (fr) | 2009-11-09 | 2019-04-03 | Wyeth LLC | Sphéroïdes de médicament enrobés et utilisations de ceux-ci pour éliminer ou réduire des affections telles que le vomissement et la diarrhée |
| EP2519664A4 (fr) | 2009-12-30 | 2014-03-12 | Avila Therapeutics Inc | Modification covalente de protéine, dirigée sur un ligand |
| WO2015103355A1 (fr) | 2014-01-01 | 2015-07-09 | Medivation Technologies, Inc. | Composés et leurs procédés d'utilisation |
| JP6769963B2 (ja) | 2014-08-29 | 2020-10-14 | ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ | α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤 |
| JP2022526713A (ja) | 2019-03-21 | 2022-05-26 | オンクセオ | がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子 |
| WO2020245208A1 (fr) | 2019-06-04 | 2020-12-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Utilisation de cd9 en tant que biomarqueur et en tant que biocible dans la glomérulonéphrite ou la glomérulosclérose |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6524832B1 (en) * | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6384051B1 (en) * | 2000-03-13 | 2002-05-07 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
| UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
| AU2002359489B2 (en) * | 2001-11-27 | 2008-10-30 | Wyeth Holdings Corporation | 3-cyanoquinolines as inhibitors of EGF-R and Her2 kinases |
-
2004
- 2004-07-28 MX MXPA06001110A patent/MXPA06001110A/es not_active Application Discontinuation
- 2004-07-28 AU AU2004266572A patent/AU2004266572A1/en not_active Abandoned
- 2004-07-28 JP JP2006522619A patent/JP2007501238A/ja active Pending
- 2004-07-28 EP EP04801904A patent/EP1648516A2/fr not_active Withdrawn
- 2004-07-28 CN CNA2004800217643A patent/CN1832757A/zh active Pending
- 2004-07-28 WO PCT/US2004/024478 patent/WO2005018677A2/fr not_active Ceased
- 2004-07-28 CA CA002533126A patent/CA2533126A1/fr not_active Abandoned
- 2004-07-28 RU RU2006106267/15A patent/RU2006106267A/ru not_active Application Discontinuation
- 2004-07-28 BR BRPI0413255-6A patent/BRPI0413255A/pt not_active Application Discontinuation
- 2004-07-28 KR KR1020067002252A patent/KR20060054412A/ko not_active Withdrawn
- 2004-07-28 US US10/900,655 patent/US20050026933A1/en not_active Abandoned
- 2004-07-29 TW TW093122704A patent/TW200515910A/zh unknown
- 2004-07-30 AR ARP040102724A patent/AR045179A1/es unknown
-
2006
- 2006-01-10 IL IL173081A patent/IL173081A0/en unknown
- 2006-01-11 CR CR8181A patent/CR8181A/es unknown
- 2006-01-25 NO NO20060398A patent/NO20060398L/no not_active Application Discontinuation
- 2006-01-30 CO CO06008204A patent/CO5640151A2/es not_active Application Discontinuation
- 2006-01-31 ZA ZA200600915A patent/ZA200600915B/en unknown
- 2006-02-01 EC EC2006006341A patent/ECSP066341A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR8181A (es) | 2006-07-14 |
| US20050026933A1 (en) | 2005-02-03 |
| WO2005018677A3 (fr) | 2006-05-26 |
| AR045179A1 (es) | 2005-10-19 |
| AU2004266572A1 (en) | 2005-03-03 |
| CN1832757A (zh) | 2006-09-13 |
| BRPI0413255A (pt) | 2006-10-03 |
| MXPA06001110A (es) | 2006-04-11 |
| NO20060398L (no) | 2006-02-28 |
| KR20060054412A (ko) | 2006-05-22 |
| EP1648516A2 (fr) | 2006-04-26 |
| ECSP066341A (es) | 2006-08-30 |
| WO2005018677A2 (fr) | 2005-03-03 |
| JP2007501238A (ja) | 2007-01-25 |
| CO5640151A2 (es) | 2006-05-31 |
| IL173081A0 (en) | 2006-06-11 |
| RU2006106267A (ru) | 2006-07-27 |
| CA2533126A1 (fr) | 2005-03-03 |
| TW200515910A (en) | 2005-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200600915B (en) | Use of combination of an epidermal growth factor receptor inhibitor and cytotoxic agents for treatment and inhibition of cancer | |
| AU2012257727B2 (en) | Method for EGFR directed combination treatment of cancer | |
| EP2799070B1 (fr) | Potentialisateur d'effet pour des agents anti-tumoraux | |
| AU6395900A (en) | Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer | |
| TWI685341B (zh) | 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| CN105120663B (zh) | 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物 | |
| Gordon et al. | A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors | |
| KR20240021237A (ko) | 두경부암 치료를 위한 egfr 저해제 | |
| WO2009002553A1 (fr) | Procédés de traitement d'un myélome multiple et de cancers résistants | |
| US20190290652A1 (en) | Method for treatment of solid malignancies including advanced or metastatic solid malignancies | |
| US20060235046A1 (en) | Use of an epidermal growth factor receptor kinase inhibitor (EGFR) in gefitinib resistant patients | |
| JP2015514796A (ja) | ２から３０ｍｇ／ｋｇの範囲の用量で癌を治療するのに使用するためのデキサナビノールまたはこの誘導体 | |
| KR20220124739A (ko) | 암의 치료를 위한 병용 요법 | |
| AU2011279835A1 (en) | Method of treating refractory cancer | |
| KR20160038895A (ko) | 암 화학 요법시의 부작용 경감제 | |
| Campas et al. | BIBW-2992. Dual EGFR/HER2 inhibitor, oncolytic. | |
| Hedgethorne et al. | Foretinib | |
| Hedgethorne et al. | Dacomitinib | |
| HK40103578A (en) | Egfr inhibitor for the treatment of head and neck cancer | |
| HK40103578B (en) | Egfr inhibitor for the treatment of head and neck cancer | |
| NZ616183B2 (en) | Method for egfr directed combination treatment of cancer |